StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BofA Securities Reiterates Underperform Rating on Fulcrum Therapeutics (FULC)
May 14, 2024 8:47 AM
BofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $5.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
After-hours movers: AMC Entertainment, StoneCo, Fulcrum Therapeutics, and more
May 13, 2024 4:47 PM
Fulcrum Therapeutics (FULC) PT Lowered to $14 at Oppenheimer
May 13, 2024 4:22 PM
Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) to Buy
May 13, 2024 4:07 PM
Fulcrum Therapeutics (FULC) PT Raised to $22 at Stifel
May 13, 2024 12:31 PM
Fulcrum Therapeutics Inc. (FULC) Tops Q1 EPS by 1c, provides guidance
May 13, 2024 7:25 AM
Form 10-Q Fulcrum Therapeutics, For: Mar 31
May 13, 2024 7:16 AM
Form 8-K Fulcrum Therapeutics, For: May 11
May 13, 2024 7:05 AM
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024 7:00 AM
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024 6:00 AM
